Victoza is the brand name for liraglutide, Novo Nordisk’s GLP-1 receptor agonist used for type 2 diabetes (and also obesity under a different label). When people talk about a “Victoza patent,” they’re usually referring to the patent protection around liraglutide itself, its specific fatty-acid modification, its manufacturing, formulations, and its uses.
Key points about the patent landscape (in general):
- There are multiple patent families covering liraglutide: the molecule itself, the specific linker/fatty-acid modification, methods of making it, formulations, and methods of use (diabetes, obesity, etc.).
- These patents are owned by Novo Nordisk and exist in many jurisdictions with different expiry dates.
- In the United States, liraglutide is also protected by regulatory data exclusivity for biologics (12 years of data exclusivity from approval), which can delay generic/biosimilar competition even after patent expiry.
- Actual expiration dates are jurisdiction-specific and can be extended by patent term adjustments/extensions. Some families may have expired in certain markets, while others or related patents may still be in force in other regions.
If you want precise, up-to-date patent numbers and expiry dates for a particular country (e.g., US, EU, UK, Japan, etc.), tell me the country and I’ll look up:
- The key liraglutide patent families and their status
- Expiry dates or likely expiry (with any extensions)
- Any related patents on formulations or methods of use
- Any relevant regulatory exclusivities (e.g., US data exclusivity)
I can also guide you to sources to check yourself (e.g., Google Patents, Espacenet, USPTO/EP Register, WIPO PATENTSCOPE) and explain how to interpret family expiry vs. regulatory exclusivity.